Enzolytics Inc. (ENZC)
USD 0.0
(7.69%)
USD 0.0
(7.69%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 365.26 Million USD | 6431.59% |
| 2022 | 5.59 Million USD | 1.16% |
| 2021 | 5.52 Million USD | -6.92% |
| 2020 | 5.93 Million USD | -14.53% |
| 2019 | 6.94 Million USD | 26.54% |
| 2018 | 5.49 Million USD | -23.24% |
| 2017 | 7.15 Million USD | 321.14% |
| 2016 | 1.69 Million USD | -0.89% |
| 2015 | 1.71 Million USD | 0.0% |
| 2010 | 724.97 Thousand USD | -48.67% |
| 2009 | 1.41 Million USD | 72.61% |
| 2008 | 818.19 Thousand USD | 85.46% |
| 2007 | 441.17 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 204.85 Million USD | -43.94% |
| 2024 Q1 | 365.42 Million USD | 0.0% |
| 2023 Q2 | 6.72 Million USD | 19.75% |
| 2023 FY | 365.26 Million USD | 6431.59% |
| 2023 Q3 | 6.38 Million USD | -5.05% |
| 2023 Q1 | 5.61 Million USD | 0.44% |
| 2022 Q2 | 7.1 Million USD | 0.0% |
| 2022 Q4 | 5.59 Million USD | -18.84% |
| 2022 FY | 5.59 Million USD | 1.16% |
| 2022 Q3 | 6.89 Million USD | -3.05% |
| 2022 Q1 | 7.1 Million USD | 0.0% |
| 2021 Q1 | 12.41 Million USD | -5.53% |
| 2021 FY | 5.52 Million USD | -6.92% |
| 2021 Q2 | 12.45 Million USD | 0.31% |
| 2021 Q3 | 12.45 Million USD | 0.05% |
| 2020 Q4 | 13.13 Million USD | 0.0% |
| 2020 FY | 5.93 Million USD | -14.53% |
| 2019 FY | 6.94 Million USD | 26.54% |
| 2018 FY | 5.49 Million USD | -23.24% |
| 2017 FY | 7.15 Million USD | 321.14% |
| 2016 FY | 1.69 Million USD | -0.89% |
| 2015 FY | 1.71 Million USD | 0.0% |
| 2011 Q1 | 800.23 Thousand USD | 10.38% |
| 2011 Q2 | 802.63 Thousand USD | 0.3% |
| 2010 Q4 | 724.97 Thousand USD | -64.09% |
| 2010 Q1 | 1.27 Million USD | -9.81% |
| 2010 FY | 724.97 Thousand USD | -48.67% |
| 2010 Q3 | 2.01 Million USD | 6.38% |
| 2010 Q2 | 1.89 Million USD | 49.01% |
| 2009 FY | 1.41 Million USD | 72.61% |
| 2009 Q4 | 1.41 Million USD | 36.31% |
| 2009 Q3 | 1.03 Million USD | 9.68% |
| 2009 Q2 | 944.68 Thousand USD | 9.44% |
| 2009 Q1 | 863.23 Thousand USD | 5.5% |
| 2008 Q1 | 26.78 Thousand USD | -93.93% |
| 2008 Q4 | 818.19 Thousand USD | 17.33% |
| 2008 Q3 | 697.31 Thousand USD | 785.29% |
| 2008 Q2 | 78.76 Thousand USD | 194.07% |
| 2008 FY | 818.19 Thousand USD | 85.46% |
| 2007 Q4 | 441.17 Thousand USD | 402.68% |
| 2007 Q3 | 87.76 Thousand USD | 0.0% |
| 2007 FY | 441.17 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -1331395.083% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -3758.78% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -404.021% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -45062.185% |
| Rebus Holdings, Inc. | 5.24 Million USD | -6868.124% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -518.953% |
| Qrons Inc. | 1.48 Million USD | -24435.894% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -29688.385% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -387.545% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -817129.833% |
| Skye Bioscience, Inc. | 14.07 Million USD | -2495.673% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -585.243% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -3712.025% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -86545.345% |
| SQZ Biotechnologies Company | 50.03 Million USD | -629.969% |
| Intellipharmaceutics International Inc. | 12 Million USD | -2941.687% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -9384.0% |
| Mesoblast Limited | 188.44 Million USD | -93.834% |
| Marizyme, Inc. | 26.67 Million USD | -1269.295% |
| Genus plc | 485 Million USD | 24.687% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -6151.801% |
| Pharming Group N.V. | 244.07 Million USD | -49.656% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -18071.414% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -14415.955% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -9512.343% |
| ContraFect Corporation | 32.53 Million USD | -1022.834% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -18335.753% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -9442.911% |
| IMV Inc. | 37.93 Million USD | -862.937% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -3001.231% |
| MultiCell Technologies, Inc. | 1617.67 USD | -22579848.073% |
| ONE Bio Corp. | 27.49 Million USD | -1228.453% |
| Accustem Sciences Inc. | 1.07 Million USD | -33745.056% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -371.82% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -17169.841% |
| Q BioMed Inc. | 8.13 Million USD | -4391.231% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -340.428% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -6998.068% |
| Biomind Labs Inc. | 1.49 Million USD | -24273.824% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -207.667% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -3939.606% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -1884.789% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -25374.509% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -256959.746% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -181521.077% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -6257.125% |
| GB Sciences, Inc. | 5.41 Million USD | -6642.32% |
| Alpha Cognition Inc. | 7.16 Million USD | -4998.124% |
| HST Global, Inc. | 593.59 Thousand USD | -61435.268% |
| CSL Limited | 18.62 Billion USD | 98.038% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -28908.186% |
| Halberd Corporation | 728.71 Thousand USD | -50024.814% |
| Agentix Corp. | 2.51 Million USD | -14449.335% |
| Resverlogix Corp. | 67.39 Million USD | -441.974% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -43450.15% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 17.908% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -21210.913% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -1376.071% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -2968.688% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -9865.967% |
| AVAX Technologies, Inc. | 3.99 Million USD | -9046.028% |
| Zenith Capital Corp. | 27.56 Thousand USD | -1324826.715% |
| Genscript Biotech Corporation | 1.32 Billion USD | 72.451% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -152953.813% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -9681.444% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -53550.236% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -13370.406% |
| Kadimastem Ltd | 3.5 Million USD | -10321.766% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -545656.019% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -626.701% |
| BioStem Technologies, Inc. | 15.9 Million USD | -2196.615% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -78503.364% |
| LadRx Corporation | 2.2 Million USD | -16499.155% |
| Cell Source, Inc. | 15.8 Million USD | -2210.847% |
| Regen BioPharma, Inc. | 5.45 Million USD | -6592.832% |
| Regen BioPharma, Inc. | 5.45 Million USD | -6592.832% |
| NovAccess Global Inc. | 7.86 Million USD | -4546.756% |
| Affymax, Inc. | 8.87 Million USD | -4017.563% |
| Itoco Inc. | 1.65 Million USD | -21995.323% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -17704.41% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -5938.503% |
| Mobile Lads Corp. | 1.31 Million USD | -27708.898% |
| CytoDyn Inc. | 127.89 Million USD | -185.603% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -873770.298% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -23219.357% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -3207.012% |
| SYBLEU INC | 681.41 Thousand USD | -53504.649% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -5886.148% |
| International Stem Cell Corporation | 5.27 Million USD | -6821.907% |
| Bioxytran, Inc. | 3.24 Million USD | -11140.777% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -58267.496% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -7811.179% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -790.987% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -1540.553% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -17934.531% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -6567.927% |
| Neutra Corp. | 973.52 Thousand USD | -37420.099% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -1158.897% |
| PureTech Health plc | 125.58 Million USD | -190.859% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -9622.036% |
| IXICO plc | 1.9 Million USD | -19121.733% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -1679.283% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -253.518% |
| CSL Limited | 18.62 Billion USD | 98.038% |
| Cellectis S.A. | 249.36 Million USD | -46.477% |